Silence Therapeutics (SLNCF) Accounts Payables (2019 - 2025)
Historic Accounts Payables for Silence Therapeutics (SLNCF) over the last 7 years, with Q3 2025 value amounting to $17.0 million.
- Silence Therapeutics' Accounts Payables rose 19164.44% to $17.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.0 million, marking a year-over-year increase of 19164.44%. This contributed to the annual value of $16.4 million for FY2024, which is 554.8% up from last year.
- Per Silence Therapeutics' latest filing, its Accounts Payables stood at $17.0 million for Q3 2025, which was up 19164.44% from $14.3 million recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' Accounts Payables registered a high of $18.8 million during Q1 2025, and its lowest value of -$18.9 million during Q2 2024.
- In the last 5 years, Silence Therapeutics' Accounts Payables had a median value of -$13.0 million in 2021 and averaged -$4.6 million.
- Its Accounts Payables has fluctuated over the past 5 years, first tumbled by 20410.78% in 2023, then skyrocketed by 24141.22% in 2025.
- Quarter analysis of 5 years shows Silence Therapeutics' Accounts Payables stood at $14.5 million in 2021, then rose by 1.94% to $14.8 million in 2022, then plummeted by 204.11% to -$15.4 million in 2023, then skyrocketed by 206.31% to $16.4 million in 2024, then grew by 3.62% to $17.0 million in 2025.
- Its Accounts Payables stands at $17.0 million for Q3 2025, versus $14.3 million for Q2 2025 and $18.8 million for Q1 2025.